摘要
背景:为实体器官移植受者提供的长期免疫抑制治疗不可避免地导致显着抑制免疫防御;这导致频繁的皮肤感染和恶性肿瘤,这是移植患者的发病率和死亡率的重要原因。与一般人群相比,实体器官移植受者皮肤癌的发病率和风险升高,基底细胞癌风险增加10倍,鳞状细胞癌风险增加50-100倍。免疫抑制药物的时间表影响皮肤恶性肿瘤的类型和时间,但内源性和外源性危险因素也起到关键作用。 方法和结果:在这里,我们将回顾表皮癌化学预防的最新进展,以便为参与移植受者管理的临床医生提供有用的信息。包括在同行评议的期刊上发表的一百一十四篇论文。 结论:化学预防将是控制高危患者皮肤癌变的关键。
关键词: 化学预防,皮肤癌,实体器官移植,免疫抑制,烟酰胺,维甲酸。
Current Medicinal Chemistry
Title:Chemoprevention of Skin Carcinomas in High-Risk Transplant Recipients
Volume: 25 Issue: 6
关键词: 化学预防,皮肤癌,实体器官移植,免疫抑制,烟酰胺,维甲酸。
摘要: Background: Long-term immunosuppressive therapy, as provided to solid organ transplant recipients, inevitably results in a significant inhibition of immune defenses; this leads to frequent skin infections and malignancies, which represent an important cause of morbidity and mortality for transplanted patients. The incidence and risk of skin carcinomas are elevated in solid organ transplant recipients in comparison with the general population, with a 10-fold increased risk for basal cell carcinoma and a 50-100-fold for squamous cell carcinoma. The schedule of immunosuppressive drugs influences the type and timing of skin malignancies, but a crucial role is also played by endogenous and exogenous risk factors.
Methods & Results: Here, we will review the state-of-the-art in chemoprevention of epidermal carcinomas in order to provide useful information for clinicians involved in the management of transplant recipients. One-hundred and forteen paper, published on peerreviewed journals, has been included.
Conclusion: Chemoprevention would be key in controlling skin carcinogenesis in high-risk patients.
Export Options
About this article
Cite this article as:
Chemoprevention of Skin Carcinomas in High-Risk Transplant Recipients, Current Medicinal Chemistry 2018; 25 (6) . https://dx.doi.org/10.2174/0929867324666171003123056
DOI https://dx.doi.org/10.2174/0929867324666171003123056 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Systemic Approach to Cancer Treatment: Tumor Cell Reprogramming Focused on Endocrine-Related Cancers
Current Medicinal Chemistry Pharmacophore Modeling and 3D QSAR Studies of Novel Human Carbonic Anhydrase IX Inhibitors
Letters in Drug Design & Discovery The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
Current Cancer Drug Targets SKINOMICS: Transcriptional Profiling in Dermatology and Skin Biology
Current Genomics Emerging Endocrine Therapies in the Treatment of HR-Positive Metastatic Breast Cancer
Current Cancer Therapy Reviews Deciphering the Role of Forkhead Transcription Factors in Cancer Therapy
Current Drug Targets The Efficacy and Mechanism of Proteasome Inhibitors in Solid Tumor Treatment
Recent Patents on Anti-Cancer Drug Discovery The Pro-Survival Function of Akt Kinase can be Overridden or Altered to Contribute to Induction of Apoptosis
Current Cancer Drug Targets Imaging of Hypoxia Using PET and MRI
Current Pharmaceutical Biotechnology Sphingolipids in Genetic and Acquired Forms of Chronic Kidney Diseases
Current Medicinal Chemistry Differential Role of Apoptosis and Autophagy Associated with Anticancer Effect of Lupulone (Hop β-Acid) Derivatives on Prostate Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Role of the Wnt/β-Catenin Pathway in the Pathogenesis of Alcoholic Liver Disease
Current Molecular Pharmacology An Analysis of Structure-function Co-relation between GLI Oncoprotein and HLA Immune-gene Transcriptional Regulation through Molecular Docking
Current Cancer Therapy Reviews Carbonic Anhydrase IX as an Anticancer Therapy Target: Preclinical Evaluation of Internalizing Monoclonal Antibody Directed to Catalytic Domain
Current Pharmaceutical Design Heat Shock Protein 90 Inhibitors in Oncology
Current Proteomics ABCC6 as a Target in Pseudoxanthoma Elasticum
Current Drug Targets TLR7/9 Antagonists as Therapeutics for Immune-Mediated Inflammatory Disorders
Inflammation & Allergy - Drug Targets (Discontinued) Purines and Pyrimidines: Metabolism, Function and Potential as Therapeutic Options in Neurodegenerative Diseases
Current Protein & Peptide Science Strategies for Non-Invasive Molecular Imaging of Acute Allograft Rejection by Gamma Scintigraphy and Positron Emission Tomography
Current Radiopharmaceuticals Commentary on “Non-Steroidal Anti-inflammatory Drugs Loaded Liposomes for Topical Treatment of Inflammatory and Degenerative Conditions” by Carla Matos, FP-ENAS-UFP Energy, Environment and Health Research Unit/CEBIMED-Centro de Estudos em Biomedicina, Fernando Pessoa University, Porto, Portugal Challenges and Prospects of Topical Treatment of Inflammatory and Degenerative Conditions: A Vesicular Approach
Current Medicinal Chemistry